Skip to content

Ardelyx ARDX Investments and Cash

Investments and Cash at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$646.1M+88.4%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:InvestmentsAndCash.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's investments and cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's investments and cash?
Ardelyx (ARDX) reported investments and cash of $238.07M in Q1 2026.
How has Ardelyx's investments and cash changed year-over-year?
Ardelyx's investments and cash increased by 11.3% year-over-year, from $213.95M to $238.07M.
What is the long-term trend for Ardelyx's investments and cash?
Over 5 years (2020 to 2025), Ardelyx's investments and cash has grown at a 7.0% compound annual growth rate (CAGR), from $188.6M to $264.69M.
What does investments and cash mean?
This represents the portion of the company's cash and investment holdings that are restricted or intended for use beyond the next twelve months. It reflects the company's long-term liquidity position and capital reserves. This metric is essential for assessing the company's ability to fund long-term strategic initiatives and R&D pipelines.